anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

02 Pattern Hunter

Loop collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 5,253
Current window 4,561-4,590
Pages 176
Rows per page 30
Loop: 02 Pattern Hunterclear collectionreset all
18 30 60

Loop

4,561-4,590 of 5,253

filter-aware
15
The slide illustrates a standard Simon 2-Stage design, a common statistical framework for Phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The table highlights patient age, gender, ECOG status, prior therapies, and cancer subtypes.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
This is a standard oncology 'swimmer's plot' or 'waterfall plot' used to demonstrate clinical efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
18
Standard clinical trial swimmer plot visualization.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
19
Includes patient enrollment status and breakdown of ORR by prior lines of therapy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
20
Standard clinical trial survival analysis charts (Kaplan-Meier) with 'Number at risk' tables below.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The slide compares clinical trial data for a specific combination therapy against historical label data for individual components.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The table compares a small sample size (N=24) against much larger historical cohorts.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
The slide uses a side-by-side comparison to highlight the superior ORR, PFS, and OS of CTX-009 compared to historical benchmarks like FOLFOX and TOPAZ-1.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
The slide outlines a 2:1 randomized clinical trial structure for a drug combination (CTX-009 + Paclitaxel) versus a control (Paclitaxel).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
25
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment options.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
26
The slide depicts a standard Simon 2-stage design, a common statistical framework in oncology clinical trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
27
The slide provides epidemiological data alongside a clinical treatment landscape overview.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
28
The slide uses a three-column layout to represent sequential or parallel development tracks.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
Includes a molecular visualization showing the binding site of CTX-471 compared to other antibodies.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
The slide uses a before-and-after visual comparison of CT scans to demonstrate drug efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide uses a process flow diagram to show the transition from testing bispecific formats to the identification of the lead candidate CTX-8371.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
35
The slide uses a visual comparison framework to contrast standard therapy (left) with the company's proprietary mechanism (right).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
36
The slide shows tumor volume reduction over time, percentage tumor growth inhibition, and individual tumor response curves, highlighting CTX-8371's efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
The slide outlines the current progress and future clinical trial design for a drug candidate.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
38
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
39
The slide uses a list-based structure to summarize drug development progress across three distinct assets.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
40
The timeline uses blue and red color coding for different drug programs or status types.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
03
Uses a cartoon illustration of a confused person to mock the company's messaging.Sarissa Capital | Activist Presentation Deck | 18 slides · Sarissa Capital
Activist deck Activist investor Beat · The MonsterLoop · Pattern Hunter1 hit
04
Uses a turtle icon to mock slow operational progress.Sarissa Capital | Activist Presentation Deck | 18 slides · Sarissa Capital
Activist deck Activist investor Beat · The MonsterLoop · Pattern Hunter1 hit
05
Uses a turtle icon to symbolize slow management response and burning money icons to symbolize capital destruction.Sarissa Capital | Activist Presentation Deck | 18 slides · Sarissa Capital
Activist deck Activist investor Beat · The MonsterLoop · Pattern Hunter1 hit
06
Uses a 'contrast-pairs' framework to highlight management's lack of accountability.Sarissa Capital | Activist Presentation Deck | 18 slides · Sarissa Capital
Activist deck Activist investor Beat · The MonsterLoop · Pattern Hunter1 hit